CClinicalTrials.gg
RecruitingNCT05015283ORDERUpdated Aug 3, 2022

Efficacy and Safety of One-anastomosis Versus Roux-en-Y Gastric Bypass for Type 2 Diabetes Remission

An interventional study of The laparoscopic One-anastomosis gastric bypass will consist of: and The laparoscopic Roux-en-Y gastric bypass will consist of: in Type2 Diabetes and Complication of Bariatric Procedure, sponsored by Beijing Friendship Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-08-03.

Sponsored by Beijing Friendship Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
248
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Diabetes mellitus (T2DM) is the most common complication of obesity patients. According to previous literature reports, weight loss and metabolic surgery are powerful means to treat obesity complicated with T2DM. Roux-en-Y gastric bypass (RYGB) is the standard operation recommended by the international society. One-anastomosis gastric bypass (OAGB) was recommended by IFSO(the International Federation for the Surgery of OBESITY AND METABOLIC DISORDERS ) in 2018.

In this study, two kinds of metabolic surgery will be compared. At present, focusing on the above two operations, only two effective randomized controlled clinical studies have been carried out, among which one single-center clinical study has been followed up for 2 years, and the primary end point is weight loss; Another multicenter study, with a 2-year follow-up, showed that the primary end point was weight loss, and the secondary index was the effectiveness of two surgical methods in the treatment of T2DM.There is still a lack of evidence-based evidence for the effectiveness and safety of the two surgical methods in the treatment of T2DM. This study will make high-level evidence about the advantages and disadvantages of OAGB and RYGB in the treatment of T2DM.

In this study, a number of centers with rich experience and clinical research experience in weight loss and metabolic surgery in Asia will be combined to complete the enrollment of 248 patients. Those who meet the standards will be randomly divided into two kinds of operations, and they will be followed up for 5 years on schedule. The rate of lost follow-up is controlled within 20%, and the data integrity is controlled within 95%. Taking the blood glucose remission rate of type 2 diabetes as the main observation index, the prospective verification shows that OAGB is clinically effective in treating obesity with type 2 diabetes compared with RYGB.

02

Conditions studied

  • Type2 Diabetes
  • Complication of Bariatric Procedure

Keywords

  • Bariatric surgery
03

In context

Diabetes Mellitus

10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.

This study's planned enrollment of 248 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

Beijing Friendship Hospital is the lead sponsor of 216 studies on the registry; 95 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 21-65 years old, Male/Female, East Asian population
  • 50 kg/m2≥BMI≥27.5kg/m2
  • Type 2 diabetes duration ≥6 months
  • HbA1c≥7.0%
  • Currently receiving one or more oral/injectable hypoglycemic drugs (insulin /glucagon-like peptide-1 receptor agonist)
  • Recommendation for OAGB/RYGB evaluated by a multidisciplinary team

Exclusion criteria

Exclusion Criteria:

  • Underwent gastrointestinal surgery (gastric/duodenal surgery or bariatric surgery)
  • Fasting C-peptide level lower than 1/2 normal minimum
  • Active gastrointestinal ulcer is present
  • Helicobacter pylori infection is present
  • A history of serious cardiovascular and cerebrovascular diseases (myocardial infarction, stroke, etc.)
  • A history of cirrhosis (Child-Pugh≥A)
  • A history of chronic kidney disease (eGFR )\< 60 ml/min / 1.73 m2)
  • Inflammatory bowel disease is present (ulcerative colitis, Crohn's disease)
  • Chronic anemia is present, Hgb for male \<100g/L, for female \<90g/L
  • A desire to conception during the study period
  • Uncontrolled mental and psychological disorders are present
  • Expected survival\<5 years of end-stage disease or previous/current malignant tumor
  • Participated in clinical studies/trials that have the conflict of interest with the study
  • Unable to understand, refuse to participate and sign the informed consent
  • Gallstones require cholecystectomy
  • Reflux esophagitis above grade A
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
248 participants (estimated)

Study arms

  • Experimental
    Laparoscopic One-anastomosis gastric bypass

    In this group, the bariatric procedure is laparoscopic one-anastomosis gastric bypass, all operations follow the same standard operating procedure.

    Procedure: The laparoscopic One-anastomosis gastric bypass will consist of:

  • Active comparator
    Laparoscopic Roux-en-Y gastric bypass

    In this group, the bariatric procedure is laparoscopic Roux-en-Y gastric bypass, all operations follow the same standard operating procedure.

    Procedure: The laparoscopic Roux-en-Y gastric bypass will consist of:

Interventions

  • ProcedureThe laparoscopic One-anastomosis gastric bypass will consist of:

    gastrointestinal anastomosis: anterior colon and posterior stomach gastrointestinal anastomosis size: diameter \< 1.5cm, linear anastomosis length 2.5cm biliary and pancreatic branches 200cm, food branches 100cm exact relationship with mesangial defect

  • ProcedureThe laparoscopic Roux-en-Y gastric bypass will consist of:

    the laparoscopic Roux-en-Y gastric bypass gastric sac size \< 30ml gastrointestinal anastomosis: anterior colon and posterior stomach gastrointestinal anastomosis size: diameter \< 1.5cm, linear anastomosis length 2.5cm biliary and pancreatic branches 50cm, food branches 150cm exact relationship with mesangial defect

06

What researchers measure

Primary outcomes

  1. One year after operation, the complete remission rate of type 2 diabetes mellitus [HbA1c < 6%, fasting plasma glucose < 5.6 mmol/L, no need to use any hypoglycemic drugs]

    Complete remission of type 2 diabetes mellitus: the blood sugar HbA1c\<6.0% and fasting plasma glucose\< 5.6 mmol/L can be controlled only by changing lifestyle intervention without taking hypoglycemic agents after operation. Partial remission: blood glucose can be controlled only by changing lifestyle intervention after operation. HbA1c\<6.5%, fasting plasma glucose 5.6\~6.9mmol/L, and blood glucose 7.8\~11.0mmol/L 2 hours after meal. Failure: blood sugar was relieved once, and then returned to the preoperative level.Unified OGTT measurement method

    Time frame: 1 year after surgery

Secondary outcomes

  1. The remission rate of type 2 diabetes mellitus

    \[HbA1c \< 6%, with or without hypoglycemic drugs\] Visit 1: Baseline Visit (Day 0-1) Visit 2:Post-op 1 month (+7 Days) Visit 3: Post-op 3 months(+7 Days) Visit 4: Post-op 6 months(14 Days) Visit 5: Post-op 12 months (+30 Days) Visit 6:Post-op 24 months (±30 Days) Visit 7:Post-op 36 months (±30 Days) Visit 8:Post-op 60 months (±30 Days)

    Time frame: 5 years after surgery

  2. The change of HbA1c

    Changes of glycosylated hemoglobin (HbA1c) compared with baseline.Visit 1: Baseline Visit (Day 0-1) Visit 2:Post-op 1 month (+7 Days) Visit 3: Post-op 3 months(+7 Days) Visit 4: Post-op 6 months(14 Days) Visit 5: Post-op 12 months (+30 Days) Visit 6:Post-op 24 months (±30 Days) Visit 7:Post-op 36 months (±30 Days) Visit 8:Post-op 60 months (±30 Days)

    Time frame: 5 years after surgery

  3. HbA1c value

    The value of HbA1c.Visit 1: Baseline Visit (Day 0-1) Visit 2:Post-op 1 month (+7 Days) Visit 3: Post-op 3 months(+7 Days) Visit 4: Post-op 6 months(14 Days) Visit 5: Post-op 12 months (+30 Days) Visit 6:Post-op 24 months (±30 Days) Visit 7:Post-op 36 months (±30 Days) Visit 8:Post-op 60 months (±30 Days)

    Time frame: 5 years after surgery

  4. The change of fasting blood glucose

    Changes of fasting blood glucose compared with baseline.Visit 1: Baseline Visit (Day 0-1) Visit 2:Post-op 1 month (+7 Days) Visit 3: Post-op 3 months(+7 Days) Visit 4: Post-op 6 months(14 Days) Visit 5: Post-op 12 months (+30 Days) Visit 6:Post-op 24 months (±30 Days) Visit 7:Post-op 36 months (±30 Days) Visit 8:Post-op 60 months (±30 Days)

    Time frame: 5 years after surgery

  5. Fasting blood glucose level

    The fasting blood glucose level.Visit 1: Baseline Visit (Day 0-1) Visit 2:Post-op 1 month (+7 Days) Visit 3: Post-op 3 months(+7 Days) Visit 4: Post-op 6 months(14 Days) Visit 5: Post-op 12 months (+30 Days) Visit 6:Post-op 24 months (±30 Days) Visit 7:Post-op 36 months (±30 Days) Visit 8:Post-op 60 months (±30 Days)

    Time frame: 5 years after surgery

  6. Fasting plasma insulin

    The value of fasting plasma insulin.Visit 1: Baseline Visit (Day 0-1) Visit 2:Post-op 1 month (+7 Days) Visit 3: Post-op 3 months(+7 Days) Visit 4: Post-op 6 months(14 Days) Visit 5: Post-op 12 months (+30 Days) Visit 6:Post-op 24 months (±30 Days) Visit 7:Post-op 36 months (±30 Days) Visit 8:Post-op 60 months (±30 Days)

    Time frame: 5 years after surgery

  7. Diabetes medication

    Follow up was used to observe whether the dosage of postoperative diabetes was reduced.Visit 1: Baseline Visit (Day 0-1) Visit 2:Post-op 1 month (+7 Days) Visit 3: Post-op 3 months(+7 Days) Visit 4: Post-op 6 months(14 Days) Visit 5: Post-op 12 months (+30 Days) Visit 6:Post-op 24 months (±30 Days) Visit 7:Post-op 36 months (±30 Days) Visit 8:Post-op 60 months (±30 Days)

    Time frame: 5 years after surgery

  8. Fasting blood lipids

    The value of fasting blood lipids.Visit 1: Baseline Visit (Day 0-1) Visit 2:Post-op 1 month (+7 Days) Visit 3: Post-op 3 months(+7 Days) Visit 4: Post-op 6 months(14 Days) Visit 5: Post-op 12 months (+30 Days) Visit 6:Post-op 24 months (±30 Days) Visit 7:Post-op 36 months (±30 Days) Visit 8:Post-op 60 months (±30 Days)

    Time frame: 5 years after surgery

  9. Changes of arterial blood pressure (SBP, DBP)

    The change of arterial blood pressure (SBP, DBP).Visit 1: Baseline Visit (Day 0-1) Visit 2:Post-op 1 month (+7 Days) Visit 3: Post-op 3 months(+7 Days) Visit 4: Post-op 6 months(14 Days) Visit 5: Post-op 12 months (+30 Days) Visit 6:Post-op 24 months (±30 Days) Visit 7:Post-op 36 months (±30 Days) Visit 8:Post-op 60 months (±30 Days)

    Time frame: 5 years after surgery

  10. The excess weight loss (%EWL) and the total weight loss (%TWL) after surgery.

    %EWL=\[(initial weight)-(post-op weight)\]/\[(initial weight)-(ideal weight)\] (in which "ideal weight" is defined by the weight corresponding to a BMI of 25 kg/m2),%TWL=\[(initial weight)-(post-op weight)\]/initial weight.Visit 1: Baseline Visit (Day 0-1) Visit 2:Post-op 1 month (+7 Days) Visit 3: Post-op 3 months(+7 Days) Visit 4: Post-op 6 months(14 Days) Visit 5: Post-op 12 months (+30 Days) Visit 6:Post-op 24 months (±30 Days) Visit 7:Post-op 36 months (±30 Days) Visit 8:Post-op 60 months (±30 Days)

    Time frame: 5 years after surgery

  11. Change waist circumference (cm) according to absolute waist circumference

    Change waist circumference (cm) according to absolute waist circumference.Visit 1: Baseline Visit (Day 0-1) Visit 2:Post-op 1 month (+7 Days) Visit 3: Post-op 3 months(+7 Days) Visit 4: Post-op 6 months(14 Days) Visit 5: Post-op 12 months (+30 Days) Visit 6:Post-op 24 months (±30 Days) Visit 7:Post-op 36 months (±30 Days) Visit 8:Post-op 60 months (±30 Days)

    Time frame: 5 years after surgery

  12. Incidence of medical and surgical complications

    Incidence of medical and surgical complications (anastomotic leakage, bile reflux, intestinal obstruction, anastomotic ulcer, anastomotic stenosis, internal hernia, chronic gastritis, esophagitis, iron deficiency anemia ...) Visit 1:Post-op 1 month (+7 Days) Visit 2: Post-op 3 months(+7 Days) Visit 3: Post-op 6 months(14 Days) Visit 4: Post-op 12 months (+30 Days) Visit 5:Post-op 24 months (±30 Days) Visit 6:Post-op 36 months (±30 Days) Visit 7:Post-op 60 months (±30 Days)

    Time frame: 5 years after surgery

  13. Incidence of surgical complications

    According to the grade of surgical complications, proportion of surgical complications in the total number.Visit 1: Baseline Visit (Day 0-1) Visit 2:Post-op 1 month (+7 Days) Visit 3: Post-op 3 months(+7 Days) Visit 4: Post-op 6 months(14 Days) Visit 5: Post-op 12 months (+30 Days) Visit 6:Post-op 24 months (±30 Days) Visit 7:Post-op 36 months (±30 Days) Visit 8:Post-op 60 months (±30 Days)

    Time frame: 5 years after surgery

  14. Surgery time

    Surgery time.Visit 1: Surgery day (day 0) record

    Time frame: Surgery day (day 0) record

  15. Average length of stay, based on the length of stay from operation (surgery day =day0) to the end of hospitalization

    Average length of stay, based on the length of stay from operation (surgery day =day0) to the end of hospitalization.Visit 1: Surgery day (day 0) record

    Time frame: 30 days after surgery

  16. Postoperative quality of life of patients, according to Impact Weight Quality Of Life questionnaire for weight loss surgery, scores were obtained

    According to Impact Weight Quality Of Life questionnaire for weight loss surgery, scores were obtained.The higher the score, the better the quality of life. Visit 1: Baseline Visit (Day 0-1) Visit 2:Post-op 1 month (+7 Days) Visit 3: Post-op 3 months(+7 Days) Visit 4: Post-op 6 months(14 Days) Visit 5: Post-op 12 months (+30 Days) Visit 6:Post-op 24 months (±30 Days) Visit 7:Post-op 36 months (±30 Days) Visit 8:Post-op 60 months (±30 Days)

    Time frame: One day before surgery,5 years after surgery

  17. Postoperative gastroesophageal reflux

    Evaluate according to gastroesophageal reflux disease questionnaire. The higher the score, the more likely there is gastroesophageal reflux. Visit 1: Baseline Visit (Day 0-1) Visit 2:Post-op 1 month (+7 Days) Visit 3: Post-op 3 months(+7 Days) Visit 4: Post-op 6 months(14 Days) Visit 5: Post-op 12 months (+30 Days) Visit 6:Post-op 24 months (±30 Days) Visit 7:Post-op 36 months (±30 Days) Visit 8:Post-op 60 months (±30 Days)

    Time frame: One day before surgery,5 years after surgery

  18. Diarrhea frequency

    Based on gastrointestinal symptom rating scale.Visit 1: Baseline Visit (Day 0-1) Visit 2:Post-op 1 month (+7 Days) Visit 3: Post-op 3 months(+7 Days) Visit 4: Post-op 6 months(14 Days) Visit 5: Post-op 12 months (+30 Days) Visit 6:Post-op 24 months (±30 Days) Visit 7:Post-op 36 months (±30 Days) Visit 8:Post-op 60 months (±30 Days)

    Time frame: One day before surgery,5 years after surgery

  19. Dumping syndrome and hypoglycemia symptoms

    Dumping syndrome and hypoglycemia symptoms.Dumping syndrome and hypoglycemia symptoms will be evaluated by questionnaire.Visit 1: Baseline Visit (Day 0-1) Visit 2:Post-op 1 month (+7 Days) Visit 3: Post-op 3 months(+7 Days) Visit 4: Post-op 6 months(14 Days) Visit 5: Post-op 12 months (+30 Days) Visit 6:Post-op 24 months (±30 Days) Visit 7:Post-op 36 months (±30 Days) Visit 8:Post-op 60 months (±30 Days)

    Time frame: 5 years after surgery

07

Study locations

1 of 1 sites recruiting
  • Beijing Friendship Hospital
    Beijing, Beijing 100050, China
    • Zhongtao Zhang, M.D.;Ph.D · Contact · zhangzht@ccmu.edu.cn · +86-13801060364
    • Zhongtao Zhang, M.D.;Ph.D · Principal investigator
    Recruiting
08

References and documents

Publications

  • Li M, Liu Y, Lee WJ, Shikora SA, Robert M, Wang W, Wong SKH, Kong Y, Tong DKH, Tan CH, Zeng N, Zhu S, Wang C, Zhang P, Gu Y, Bai R, Meng F, Mao Z, Zhao X, Wu L, Liu Y, Zhang S, Zhang P, Zhang Z. Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass for type 2 diabetes remission (ORDER): protocol of a multicentre, randomised controlled, open-label, superiority trial. BMJ Open. 2022 Sep 29;12(9):e062206. doi: 10.1136/bmjopen-2022-062206. PubMed 36175102 ↗

Individual participant data

Plan to share: Yes — 1. Will individual deidentified participant data (including data dictionaries) will be shared: Yes 2. what data in particular will be shared: Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices). 3. what other documents will be available: study portocol 4. when will data be availuble (start and end dates): Beginning 6 months and ending 24 months following article publicaiton. 5. With whom: Investigators whose proposed use of the data has been approved by an independent review commmittee identified for this purepose. 6. For what types of analysis: For individual participant data meta-analysis. 7. By what mmechanism will data be made available: Proposals should be directed to zhangzht@ccmu.edu.cn to gain access, data requestors will need to sign a data access agreement.

Supporting information: Study protocol

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05015283
Lead sponsor
Beijing Friendship Hospital
Collaborators
Beijing Tiantan Hospital, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, The Third Xiangya Hospital of Central South University, The First Affiliated Hospital of Soochow University, The Third People's Hospital of Chengdu, Taipei Medical University Hospital
Responsible party
Zhongtao Zhang (Director of general surgery, principal investigator, Beijing Friendship Hospital) — Principal investigator
First posted
Aug 20, 2021
Start date
Feb 1, 2022
Primary completion
Oct 1, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 3, 2022

Study contacts

Zhongtao Zhang, M.D.;Ph.D
Contact
zhangzht@ccmu.edu.cn
+86-13801060364
Mengyi Li, M.D
Contact
limengyi@ccmu.edu.cn
+86-15810993198
Zhongtao Zhang, M.D.;Ph.D
principal investigator · Beijing Friendship Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion